No connection

Search Results

KYNB vs LFWD

KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%
LFWD
Lifeward Ltd.
BEARISH
Price
$6.57
Market Cap
$24.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KYNB
--
LFWD
--
Forward P/E
KYNB
-0.7
LFWD
-5.21
P/B Ratio
KYNB
-0.97
LFWD
1.19
P/S Ratio
KYNB
4.51
LFWD
1.13
EV/EBITDA
KYNB
0.13
LFWD
-0.71

Profitability

Gross Margin
KYNB
-273.8%
LFWD
38.25%
Operating Margin
KYNB
-1058.65%
LFWD
-112.69%
Profit Margin
KYNB
2848.63%
LFWD
-90.38%
ROE
KYNB
--
LFWD
-146.12%
ROA
KYNB
-16.96%
LFWD
-40.97%

Growth

Revenue Growth
KYNB
-59.3%
LFWD
-32.7%
Earnings Growth
KYNB
--
LFWD
--

Financial Health

Debt/Equity
KYNB
4.37
LFWD
0.52
Current Ratio
KYNB
3.39
LFWD
1.31
Quick Ratio
KYNB
3.19
LFWD
0.69

Dividends

Dividend Yield
KYNB
--
LFWD
--
Payout Ratio
KYNB
0.0%
LFWD
0.0%

AI Verdict

KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)
LFWD BEARISH

LFWD exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a collapse in top-line growth with revenue declining by 32.7% YoY, coupled with an unsustainable operating margin of -112.69%. Despite a low Price/Book ratio, the massive negative ROE (-146.12%) and consistent earnings misses (0/4 in the last year) suggest a failing business model. The extreme disconnect between the current price ($6.57) and the analyst target ($20.00) is not supported by any available fundamental data.

Strengths
Positive Gross Margin (38.25%)
Low Debt/Equity ratio (0.52) relative to sector average
Current Ratio above 1.0 (1.31)
Risks
Severe revenue contraction (-32.7% YoY)
Extreme profitability decay (Profit Margin -90.38%)
Critical Piotroski F-Score (1/9) signaling high risk

Compare Another Pair

KYNB vs LFWD: Head-to-Head Comparison

This page compares Kyntra Bio, Inc. (KYNB) and Lifeward Ltd. (LFWD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile